• Capex and expansion: Sai Life is targeting a capex of ₹1,100 to ₹1,300 crore funded through internal accruals and debt, expanding manufacturing capacity from 700 kiloliters to 1,150 kiloliters by the end of FY27.
• Growth and margins: Management maintains a 3- to 5-year revenue growth guidance of 15% to 20% and an EBITDA margin band of 28% to 30%, factoring in recent cost increases in solvents and logistics.
• Molecule pipeline: The company has 11 phase-3 molecules expected to commercialize over the next 18 to 24 months, alongside 34 already-commercial molecules, three of which will begin contributing meaningful revenue in FY27.
• Revenue mix: Pure-play research accounts for 35% to 40% of revenue while development and manufacturing generate 60% to 65%, a ratio expected to remain stable over the next two years.
• Asset turnover target: Management anticipates achieving a net asset turn of 1.2 to 1.4 times around FY28–FY29, though it is willing to invest ahead of schedule if high-growth CDMO opportunities emerge.